TNFSF10 and neoplasm: Once packed with TNF-related apoptosis-inducing ligand and anti-angiogenic drug cilengitide, such carriers resided at the tumor site, collated in depots, continued cargo activation, decreased tumor vascularization, and slowed significantly tumor growth without adverse side effects.